Business Standard

Corbevax becomes third Covid vaccine to be approved for children in India

Biological E's Corbevax gets DCGI nod based on interim results from phase 2/3 studies

Corbevax is third Covid vaccine to be approved for children in India
Premium

The Corbevax vaccine is administered through an intramuscular route with two doses scheduled 28 days apart and is stored at 2 to 8 degrees’ Celsius temperature

Sohini Das Mumbai
A third Covid-19 vaccine for children has now obtained the Indian drug regulator’s nod. Biological E’s (BE) receptor binding domain (RBD) protein sub-unit vaccine against Covid-19 has been granted an emergency use authorisation (EUA) from the Drugs Controller General of India (DCGI). based on interim results of the ongoing phase-2 and 3 clinical study.

Cadila Healthcare’s ZyCoV-D and Bharat Biotech’s Covaxin are two vaccines that have already been approved in this category. Of these, Covaxin is already in use for vaccinating adolescents 15-17 years. Covaxin got a recommendation for approval to be used in children as young as two year

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 21 2022 | 6:39 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com